Prognosis for Untreated 14-mm Gleason 7 (3+4) Prostate Cancer
Without treatment, a 14-mm Gleason 7 (3+4) prostate cancer carries a significant risk of progression and cancer-specific mortality, with an estimated 10-year disease-specific survival of approximately 56-62% based on historical cohort data, though this varies substantially based on patient age and comorbidities.
Natural History and Disease-Specific Outcomes
The natural history of untreated Gleason 7 prostate cancer is well-documented in historical cohorts. In a population-based study of conservatively treated localized prostate cancer, men with Gleason scores 5-7 experienced a maximum estimated loss of life expectancy of 4-5 years compared to the general population 1. A separate cohort study found that the disease-specific mean survival for Gleason score 7 was approximately 10 years without curative treatment 2.
More specifically, at least one out of three patients with untreated prostate cancer will die from the disease within 10 years 3, though this risk is heavily influenced by tumor grade. The 10-year disease-specific survival for Gleason 7 tumors managed conservatively is approximately 56% 2.
Critical Distinction: Gleason 3+4 vs 4+3
Your specific tumor is Gleason 3+4, which is prognostically more favorable than Gleason 4+3. There is a trend toward longer survival for Gleason 3+4 (disease-specific mean survival 13 years) compared to Gleason 4+3 (9 years) 2. This distinction matters significantly for prognosis.
Risk of Progression Without Treatment
The PSA is likely to rise and the tumor will grow with time—patients should not expect the tumor to remain stable indefinitely 4. Key progression risks include:
- Possible cancer progression or metastasis before treatment 4
- Risk of upgrading to higher Gleason patterns (pattern 4 or 5) on subsequent biopsies 4
- Potential need for more complex treatment with greater side effects if the cancer progresses 4
In active surveillance cohorts (which represent a monitored form of conservative management), approximately 30-35% of patients show histologic progression requiring treatment 5. However, these are selected low-risk patients, not intermediate-risk Gleason 7 cases.
Tumor Size Considerations
Your 14-mm tumor represents a relatively small focus. In active surveillance studies, negative follow-up biopsies were more prevalent in patients with small volume of malignancy 6, suggesting that tumor volume matters for progression risk. However, Gleason 7 disease is generally not recommended for active surveillance in patients with life expectancy >10 years 7.
Competing Mortality Risks
The actual risk to your life depends critically on:
- Your age and baseline life expectancy 4
- Comorbidities - these are powerful independent predictors of survival 1
- Overall health status 4
If your life expectancy is less than 10 years due to age or comorbidities, the risk of dying from prostate cancer may be lower than dying from other causes 1.
Quality of Life Without Treatment
Without treatment, most men do NOT develop sexual or urinary problems within five years from the cancer itself 3. The most common complications of untreated prostate cancer are actually "none" in the short to medium term 3. This contrasts sharply with treatment-related side effects, where impotence is the most common complication after both surgery and radiation 3.
Clinical Context and Caveats
This is intermediate-risk disease (Gleason 7), not low-risk disease. The NCCN guidelines clearly state that active surveillance of unfavorable intermediate and high-risk clinically localized cancers is not recommended in patients with life expectancy >10 years (category 1) 7.
A randomized trial comparing radical prostatectomy with watchful waiting showed significant improvements in disease-specific survival, overall survival, and risk of metastasis with surgery 5, though this included mostly lower-grade tumors.
Bottom Line
For a 14-mm Gleason 3+4 prostate cancer without treatment:
- 10-year disease-specific mortality risk: approximately 40-45%
- Expected loss of life expectancy: 4-5 years (if otherwise healthy)
- High likelihood of tumor growth and PSA rise over time
- Risk of progression to higher-grade disease requiring more aggressive treatment
The decision to defer treatment must weigh these substantial cancer-related risks against treatment side effects, your age, comorbidities, and personal values 4, 8.